TWI848990B - 治療化療難治性癌症的新聯合用藥方案 - Google Patents

治療化療難治性癌症的新聯合用藥方案 Download PDF

Info

Publication number
TWI848990B
TWI848990B TW108136944A TW108136944A TWI848990B TW I848990 B TWI848990 B TW I848990B TW 108136944 A TW108136944 A TW 108136944A TW 108136944 A TW108136944 A TW 108136944A TW I848990 B TWI848990 B TW I848990B
Authority
TW
Taiwan
Prior art keywords
cancer
compound
formula
administered
pharmaceutically acceptable
Prior art date
Application number
TW108136944A
Other languages
English (en)
Chinese (zh)
Other versions
TW202027738A (zh
Inventor
李嘉強
Original Assignee
大陸商北京強新生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京強新生物科技有限公司 filed Critical 大陸商北京強新生物科技有限公司
Publication of TW202027738A publication Critical patent/TW202027738A/zh
Application granted granted Critical
Publication of TWI848990B publication Critical patent/TWI848990B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108136944A 2018-10-12 2019-10-14 治療化療難治性癌症的新聯合用藥方案 TWI848990B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811195239.3 2018-10-12
CN201811195239 2018-10-12

Publications (2)

Publication Number Publication Date
TW202027738A TW202027738A (zh) 2020-08-01
TWI848990B true TWI848990B (zh) 2024-07-21

Family

ID=70163618

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108136944A TWI848990B (zh) 2018-10-12 2019-10-14 治療化療難治性癌症的新聯合用藥方案

Country Status (15)

Country Link
US (2) US12257227B2 (https=)
EP (1) EP3865130A4 (https=)
JP (2) JP7513286B2 (https=)
CN (2) CN120168498A (https=)
AU (1) AU2019357933B2 (https=)
BR (1) BR112021006898A2 (https=)
CA (1) CA3115869A1 (https=)
EA (1) EA202190771A1 (https=)
IL (1) IL282228A (https=)
MX (1) MX2021004151A (https=)
PH (1) PH12021550815A1 (https=)
SG (1) SG11202103707TA (https=)
TW (1) TWI848990B (https=)
WO (1) WO2020074010A1 (https=)
ZA (1) ZA202102494B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201731500A (zh) * 2016-01-20 2017-09-16 波士頓生醫公司 用於治療癌症的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) * 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201731500A (zh) * 2016-01-20 2017-09-16 波士頓生醫公司 用於治療癌症的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Hiroki Sakamoto1 Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial Journal of Gastroenterology 41 2006 70-76 *

Also Published As

Publication number Publication date
CN120168498A (zh) 2025-06-20
US20250235425A1 (en) 2025-07-24
CN113164438B (zh) 2025-03-18
PH12021550815A1 (en) 2021-10-04
JP7513286B2 (ja) 2024-07-09
JP2024123152A (ja) 2024-09-10
JP2022504760A (ja) 2022-01-13
AU2019357933A1 (en) 2021-05-20
EP3865130A1 (en) 2021-08-18
MX2021004151A (es) 2021-09-08
BR112021006898A2 (pt) 2021-07-20
EA202190771A1 (ru) 2021-09-07
CA3115869A1 (en) 2020-04-16
EP3865130A4 (en) 2022-07-20
IL282228A (en) 2021-05-31
SG11202103707TA (en) 2021-05-28
AU2019357933B2 (en) 2023-11-23
US12257227B2 (en) 2025-03-25
US20210393571A1 (en) 2021-12-23
TW202027738A (zh) 2020-08-01
KR20210076951A (ko) 2021-06-24
WO2020074010A1 (zh) 2020-04-16
ZA202102494B (en) 2023-01-25
CN113164438A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20190224157A1 (en) Methods for treating cancer
US20180085341A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
CN107683137A (zh) 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
WO2016168858A1 (en) Methods for treating cancer
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
HK40124738A (zh) 治疗化疗难治性癌症的新联合用药方案
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer